CFG
IBRX icon

Carr Financial Group’s ImmunityBio IBRX Stock Holding History

Carr Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Sell
207,288
-44,340
-18% -$336K 0.42% 43
2026
Q1 		$1.93M Buy
+251,628
New +$1.72M 0.51% 39

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carr Financial Group's IBRX Position: Q2 2026 in Review

Carr Financial Group reduced its ImmunityBio (IBRX) stake by 18% in Q2 2026, selling an estimated $336K and leaving 207,288 shares worth $1.81M. The position accounts for 0.42% of the portfolio, ranked #43.

Carr Financial Group first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.93M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Carr Financial Group held 207,288 shares of ImmunityBio worth $1.81M as of Q2 2026.
  • Carr Financial Group sold 44,340 ImmunityBio shares in Q2 2026, an estimated $336K.
  • ImmunityBio made up 0.42% of Carr Financial Group's portfolio in Q2 2026, its #43 holding.
  • Carr Financial Group first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Carr Financial Group's ImmunityBio position peaked at $1.93M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Carr Financial Group's 13F filing for Q2 2026, filed 6 Aug 2026.